Welcome to our dedicated page for Resverlogix news (Ticker: RVXCF), a resource for investors and traders seeking the latest updates and insights on Resverlogix stock.
Resverlogix Corp. develops epigenetic therapies, with its clinical program centered on apabetalone for cardiovascular disease, associated comorbidities, and post COVID-19 conditions. The company describes apabetalone as a candidate designed to regulate expression of disease-causing genes and restore biological functions altered by chronic illness.
Resverlogix news commonly covers apabetalone research, BETonMACE-related cardiovascular data, clinical and commercial-development partnerships, continuous disclosure status, management cease trade order matters, shareholder meeting results, board composition, and debt or debenture actions.
Resverlogix Corp. (RVXCF) announced a shift in focus towards the prevention and treatment of Post COVID-19 Conditions (PCC), commonly referred to as long-COVID. This decision follows feedback from the FDA and highlights the potential of apabetalone to support patients affected by lingering COVID symptoms. The CDC estimates that one in three US adults may experience long-COVID, creating a significant market opportunity. Apabetalone, a first-in-class therapeutic candidate, has a well-established safety profile and is set to enter Phase 3 trials in 2023, with support from EVERSANA™ for global commercialization.